Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK16149 DDI with Probenecid or Cimetidine
NCT05881811Phase 1Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of crisugabalin besilate in postherpetic neuralgia (PHN) (4 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Started Mar 2023; status: completed.
02
Drugs
crisugabalin besilate
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT05881811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05881811.